Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 3'-untranslated regions (3'-UTRs) of messenger RNAs (mRNAs) encoding components of the renin-angiotensin system (RAS)—including renin, angiotensinogen (AGT), angiotensin-converting enzyme (ACE), and the angiotensin II type 1 receptor (AT1R)—serve as critical hubs for post-transcriptional regulation (Kemp et al., 2014, J Am Soc Hypertens). These regions contain binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that dictate the stability and translation efficiency of the transcripts (Marques et al., 2015, Reviews in Cardiovascular Medicine). By modulating these interactions, the cell can fine-tune the activity of the RAS, which is the primary hormonal system regulating blood pressure and fluid balance. Dysregulation of these 3'-UTR-mediated pathways, such as the loss of miR-181a or miR-155 mediated suppression, is frequently implicated in the pathogenesis of hypertension and renal fibrosis (Nossent et al., 2013, Circulation Research). Consequently, these regulatory sequences are emerging as novel therapeutic targets for RNA-based interventions, such as miRNA mimics or antisense oligonucleotides like Zilebesiran, designed to suppress overactive RAS components (Jackson et al., 2021, Frontiers in Genetics). Such approaches offer a more precise method of control compared to traditional small-molecule inhibitors or receptor blockers, though challenges remain regarding delivery and off-target effects.
RNA interference (RNAi) or antisense-mediated degradation and translational repression of RAS component transcripts by targeting specific sequences within the 3'-untranslated regions.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Renin-angiotensin system component messenger RNA 3'-untranslated regions (RAS mRNA 3'-UTRs).